Trulicity Lawsuit: NAION Vision-Loss Claims Under the Current Criteria

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Which Medications — and Which Injuries — Qualify

Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Trulicity is Eli Lilly’s brand of dulaglutide, the longest-marketed medication in this litigation, and under the current GLP-1 referral criteria it qualifies for the NAION sudden vision-loss track only — the stomach-injury track is limited to brand-name semaglutide (Ozempic, Wegovy, Rybelsus). Marin & Murphy is currently accepting Ozempic (GLP-1) NAION cases.

Which track Trulicity fits — the first thing to settle

• NAION vision-loss track — Trulicity qualifies. The referral criteria for non-arteritic anterior ischemic optic neuropathy cover brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound. What is required is an actual NAION diagnosis, made while taking the medication or after stopping, with some degree of permanent vision impairment.
• Stomach-injury track — Trulicity does not currently qualify. Gastroparesis and gastric-obstruction claims under these criteria require brand-name semaglutide. Trulicity, Mounjaro, and Zepbound do not meet them as written.

As with the other Eli Lilly products, there is a nuance the court records make plain. Trulicity is named on the Eastern District of Pennsylvania’s product list for the stomach-injury MDL, and Eli Lilly is an active defendant there. The intake criteria are narrower than the MDL’s scope. That means a Trulicity user with a hospital-documented stomach injury is not out on any court ruling — they simply fall outside how this particular referral pathway is currently drawn. That is a reason to have the conversation, not to skip it.

Trulicity’s place in the litigation

Trulicity has been on the market longer than any other medication in these cases, and its patient population skews toward type 2 diabetes management rather than weight loss. That matters in two practical ways: exposure periods are often much longer, and the average age of a Trulicity claimant tends to run higher — which happens to overlap with the age band where NAION most often occurs, the mid-sixties.

Trulicity is named in the JPML’s December 15, 2025 order creating MDL 3163, the federal NAION proceeding, and among the six medications covered by New Jersey’s two GLP-1 multicounty litigations designated by Supreme Court order on October 16, 2025 and noticed to the bar on November 10, 2025 (Bergen County, Judge Gregg A. Padovano). Two of the founding federal NAION cases name Eli Lilly directly: Morris v. Eli Lilly & Co., E.D. Pa. No. 2:25-cv-04106, and Garcia v. Eli Lilly & Co., E.D. Pa. No. 2:25-cv-04537, both among the actions attached to Lilly’s own motion to consolidate.

What the FDA adverse-event data shows for dulaglutide

As of the July 30, 2026 data refresh, FDA’s FAERS database held 88,160 total reports and 22,898 serious reports for dulaglutide, including 1,829 coded as impaired gastric emptying, 388 for intestinal obstruction, 255 for ileus, 1,400 for visual impairment, and 202 for blindness. Reports submitted to FDA are not verified and do not establish causation; they are voluntary, unvalidated, subject to duplication, and driven in volume by how long a drug has been marketed and how much attention it has received.

Said plainly: the specific FAERS term used for NAION does not appear among dulaglutide’s top 200 reported reactions, while it appears 631 times for semaglutide. The published NAION research — the July 3, 2024 JAMA Ophthalmology cohort study and the European Medicines Agency’s June 6, 2025 conclusion that NAION is a very rare side effect — has concentrated on semaglutide. Report counts cannot be used to compare risk between drugs, and the NAION criteria include Trulicity because the individual diagnosis, not the database, governs eligibility.

Who may qualify

• NAION — the Trulicity track: use of brand-name Trulicity (or Mounjaro, Zepbound, Ozempic, Wegovy, Rybelsus); an actual NAION diagnosis made while taking the medication or after stopping; and some degree of permanent vision impairment. These criteria state no age cutoff, no diagnosis-date cutoff, and no hospitalization requirement.
• Helpful for the review: the name of the practice that diagnosed it, the date vision changed, which eye, your start and stop dates on Trulicity, and whether giant-cell arteritis was ruled out. Missing pieces are fine — records fill most of them in.
• Stomach injuries: outside the current Trulicity criteria. If you had a documented gastroparesis or obstruction diagnosis with an emergency-room visit or hospital admission, tell us anyway; that routes to a review, not a refusal.
• Generic or compounded products do not meet the brand-name requirement in either track. If you are unsure what you were dispensed, pharmacy records generally answer it.
• Not your doctor. These are claims against the manufacturer, Eli Lilly — not against the endocrinologist or primary care physician who prescribed a drug whose label said what it said.

If you are asking on someone else’s behalf

A large share of the people who research NAION are not the patient. It is frequently a spouse or an adult child, working from what a doctor said in an appointment they attended. If that is you: you are in the right place, you do not need anyone’s permission to gather information, and asking does not commit the patient to anything. Bring what you know and we will tell you what is missing.

Where things stand as of October 2026

MDL 3163, the federal NAION proceeding, was created December 15, 2025. On July 2, 2026 the court granted the defendants’ request for early discovery and motion practice on general causation and preemption, and directed the parties to exchange fact sheets and medical records confirming proof of use and proof of diagnosis. On July 21, 2026 it appointed a special discovery master. Case Management Order No. 14 (August 27, 2026) set the expert schedule, with plaintiffs’ expert reports due March 26, 2027; there is no bellwether pool and no trial date.

In the older stomach-injury MDL, a Rule 702 hearing on general causation, preemption, and warning adequacy was held September 14 through 18, 2026, and the most significant ruling to date — August 15, 2025, requiring objective gastric-emptying testing for gastroparesis claims — went in the defendants’ favor. Nobody can honestly tell you how this ends.

Common questions

Other GLP-1 medications: Wegovy, Rybelsus, Mounjaro, Zepbound, and compounded semaglutide. The manufacturer: Eli Lilly.